Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO
July 12 2017 - 2:56PM
Business Wire
Newman Ferrara LLP announced today that the firm is conducting
an investigation on behalf of shareholders of Agios Pharmaceuticals
Inc. (“Agios” or the “Company”) (NASDAQ:AGIO) into potential
breaches of fiduciary duty by the Company’s Board of Directors (the
“Board”).
Agios, headquartered in Cambridge, MA, is a clinical-stage
biopharmaceutical company, focused on the treatment of cancer and
rare genetic metabolic disorders. Newman Ferrara’s investigation
focuses on decisions made by the Board, without shareholder
approval, the result of which significantly diminish shareholder
value and do not benefit the Company. Considering the Company’s
lackluster performance since its 2013 initial public offering, it
is clear that the Board lacks the ability to fairly assess and
oversee the Company’s direction and leadership.
Current Agios stockholders seeking more information on this
matter are invited to contact Newman Ferrara attorneys Jeffrey
Norton (jnorton@nfllp.com) or Roger Sachar, Jr. (rsachar@nfllp.com)
to discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New
York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder
litigation, consumer protection, civil rights, and real estate. For
more information, please visit the firm website at
www.nfllp.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170712006166/en/
Newman Ferrara LLPJeffrey M. Norton,
212-619-5400jnorton@nfllp.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2023 to Apr 2024